Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A nephropathy (IgAN), a chronic kidney disease. The Japanese biopharma is now looking ahead to a prospective phase 3 trial of mezagitamab. The data was presented at the European Renal Association Congress on 6 June 2025 […]
The post Takeda presents positive results from trial of chronic kidney disease treatment appeared first on Pharmafile.
